Repurposed Alcoholism Drug Disulfiram Exploits Genetic Vulnerability to Target APC-Deficient Colorectal Cancer Cells

New research shows the alcoholism drug disulfiram can kill APC-deficient colorectal cancer cells by triggering fatal oxidative stress through ALDH2 inhibition.

By: AXL Media

Published: Apr 7, 2026, 6:50 AM EDT

Source: Information for this report was sourced from Compuscript Ltd and Genes & Diseases.

Synthetic Lethality Offers New Path for Colorectal Treatment

A breakthrough in oncology research has identified a method to target a specific genetic weakness present in the vast majority of colorectal cancer cases. Scientists focused on the adenomatous polyposis coli (APC) gene, a tumor suppressor that is mutated in 60 to 85 percent of patients. Because restoring the function of a mutated APC gene is biologically difficult, the research team utilized a synthetic lethal approach to find an alternative target. This led to the discovery of aldehyde dehydrogenase 2 (ALDH2) as a critical partner; when ALDH2 is inhibited in cells already lacking the APC gene, the cancer cells can no longer survive.

Repurposing Established Medications for Targeted Oncology

The study highlights the efficacy of disulfiram, a medication traditionally prescribed to treat alcoholism, as a potent inhibitor of ALDH2 in a cancer context. Findings published on April 6, 2026, show that disulfiram specifically reduces the proliferation of cancer cells with APC deficiencies while sparing healthy cells that possess a functional, wild-type version of the gene. This selectivity is a cornerstone of the research, suggesting that the drug could offer a targeted treatment option with fewer systemic side effects than traditional chemotherapy. Because disulfiram is already an approved medication, it presents a cost-effective opportunity for drug repurposing in gastrointestinal medicine.

Molecular Mechanisms of Oxidative Stress and Cell Death

The biological mechanism driving this treatment involves the manipulation of reactive oxygen species (ROS) within the tumor environment. The loss of the APC gene naturally predisposes cancer cells to higher levels of these volatile molecules. When disulfiram is introduced to inhibit ALDH2, it forces a continuous and overwhelming accumulation of ROS that the cell cannot manage. This extreme oxidative stress activates the ASK1/JNK signaling pathway, a cascade that essentially orders the cancer cell to undergo apoptosis, or programmed cell death.